Now showing items 1-20 of 22

    • The abandoned trials of pre-exposure prophylaxis for HIV : what went wrong? 

      Singh, Jerome Amir.; Mills, Edward J. (Plos., 2005-09)
      Discusses the impact of irresponsible reporting and activism against the use of the oral antiretroviral drug tenofovir as a pre-exposure prophylaxis (PREP) for HIV/AIDS. Protests against trials of PREP; Concerns of the ...
    • An adaptive design to bridge the gap between phase 2b/3 microbicide effectiveness trials and evidence required for licensure. 

      Taylor, Douglas.; Grobler, Anna Christina.; Abdool Karim, Salim Safurdeen. (Sage., 2012-05-18)
      Background. Vaginally and rectally applied microbicides are being developed to help prevent sexual acquisition of HIV. Due to the lack of surrogate outcomes, the path toward licensure typically moves directly from expanded ...
    • An AIDS-Free Generation? 

      Abdool Karim, Salim Safurdeen. (American Association for the Advancement of Science., 2012-07-13)
      No abstract available.
    • Antiretroviral prophylaxis for HIV prevention reaches a key milestone. 

      Abdool Karim, Salim Safurdeen.; Abdool Karim, Quarraisha. (Elsevier., 2012-06-02)
      No abstract available.
    • ARV-based HIV prevention for women Á where are we in 2014. 

      Mastro, Timothy D.; Sista, Nirupama.; Abdool Karim, Quarraisha. (International AIDS Society., 2014)
      Abstract available in pdf.
    • Balancing efficiency, equity and feasibility of HIV treatment in South Africa – development of programmatic guidance. 

      Baltussen, Rob.; Mikkelsen, Evelinn.; Tromp, Noor.; Hurtig, AnneKarin.; Byskov, Jens.; Olsen, Oystein.; Baeroe, Kristine.; Hontelez, Jan A.; Singh, Jerome Amir.; Norheim, Ole F. (BioMed Central., 2013-10-09)
      South Africa, the country with the largest HIV epidemic worldwide, has been scaling up treatment since 2003 and is rapidly expanding its eligibility criteria. The HIV treatment programme has achieved significant results, ...
    • Challenges in HIV-prevention microbicide research. 

      Harrison, Polly.; Mellors, John W.; Richardson, Barbra A.; Masse, Benoıt.; Abdool Karim, Quarraisha.; Abdool Karim, Salim Safurdeen.; Cates, Ward.; Coletti, Anne.; Derbyshire, Janet.; Dorflinger, Laneta J.; Feldblum, Paul.; Gabelnick, Henry.; Halpern, Vera Grigorieva.; Jespers, Vicky.; Kharsany, Ayesha B. M.; McCormack, Sheena.; Nunn, Andrew.; McGowan, Ian.; Omar, Rabeea F.; Padian, Nancy S.; Pedneault, Louise.; Robbiani, Melissa Pope.; Sailer, James.; Taylor, Douglas.; Tolley, Elizabeth E.; Van Damme, Lut.; Vermund, Sten H.; Van de Wijgert, Janneke. (American Association for the Advancement of Science., 2008-12-17)
      No abstract available.
    • Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS. 

      Shey, Muki S.; Kongnyuy, Eugene J.; Alobwede, Samuel M.; Wiysonge, Charles Shey. (The Cochrane Collaboration., 2013-03-28)
      The primary objective of this review was to evaluate the antiviral efficacy of co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection. The secondary objectives were to evaluate the safety and ...
    • Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. 

      Abdool Karim, Salim Safurdeen.; Abdool Karim, Quarraisha.; Frohlich, Janet A.; Grobler, Anna Christina.; Baxter, Cheryl.; Mansoor, Leila E.; Kharsany, Ayesha B. M.; Sibeko, Sengeziwe.; Mlisana, Koleka Patience.; Omar, Zaheen.; Gengiah, Tanuja N.; Maarschalk, Silvia.; Arulappan, Natasha.; Mlotshwa, Mukelisiwe.; Morris, Lynn.; Taylor, Douglas. (American Association for the Advancement of Science., 2010-09)
      The Centre for the AIDS Program of Research in South Africa (CAPRISA) 004 trial assessed the effectiveness and safety of a 1% vaginal gel formulation of tenofovir, a nucleotide reverse transcriptase inhibitor, for the ...
    • Empowering women in human immunodeficiency virus prevention. 

      Abdool Karim, Quarraisha.; Humphries, Hilton Richard.; Stein, Zena. (Elsevier., 2012-08-01)
      Women comprise one-half of people infected with the human immunodeficiency virus in the world, and about 70% of them live in sub-Saharan Africa. Advancing, untreated HIV disease in women has resulted in substantial declines ...
    • Factors affecting first-month adherence to antiretroviral therapy among HIV-positive adults in South Africa. 

      Maqutu, Dikokole.; Zewotir, Temesgen.; North, Delia Elizabeth.; Naidoo, Kogieleum.; Grobler, Anna Christina. (Taylor & Francis co-published with NISC., 2010-09-22)
      This study explores the influence of baseline factors on first-month adherence to highly active antiretroviral therapy (HAART) among adults. The study design involved a review of routinely collected patient information in ...
    • HIV pre-exposure prophylaxis in injecting drug users. 

      Abdool Karim, Salim Safurdeen. (Elsevier., 2013-06-15)
      No abstract available.
    • Innate immune activation enhances HIV acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. 

      Naranbhai, Vivek.; Abdool Karim, Salim Safurdeen.; Altfeld, Marcus.; Samsunder, Natasha.; Durgiah, Raveshni.; Sibeko, Sengeziwe.; Abdool Karim, Quarraisha.; Carr, William Henry. (Oxford University Press., 2012-09-01)
      The antiretroviral agent, tenofovir, formulated as a vaginal microbicide gel, reduces human immunodeficiency virus (HIV) acquisition by 39% in women. This study assessed the role of preexisting immune activation in ...
    • Integration of antiretroviral therapy with tuberculosis treatment. 

      Abdool Karim, Salim Safurdeen.; Naidoo, Kogieleum.; Grobler, Anna Christina.; Padayatchi, Nesri.; Baxter, Cheryl.; Gray, Andrew L.; Gengiah, Tanuja N.; Gengiah, Santhanalakshmi.; Naidoo, Anushka.; Jithoo, Niraksha.; Nair, Gonasagrie.; El-Sadr, Wafaa.; Friedland, Gerald H.; Abdool Karim, Quarraisha. (Massachusetts Medical Society., 2011-10-20)
      Background. We previously reported that integrating antiretroviral therapy (ART) with tuberculosis treatment reduces mortality. However, the timing for the initiation of ART during tuberculosis treatment remains ...
    • Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. 

      Moore, Penny L.; Sheward, Daniel.; Nonyane, Molati.; Ranchobe, Nthabeleng.; Hermanus, Tandile.; Gray, Elin S.; Abdool Karim, Salim Safurdeen.; Williamson, Carolyn.; Morris, Lynn. (American Society for Microbiology., 2013-02-13)
      Broadly cross-neutralizing (BCN) antibodies are likely to be critical for an effective HIV vaccine. However, the ontogeny of such antibodies and their relationship with autologous viral evolution is unclear. Here, we ...
    • Natural killer cell function in women at high risk for HIV acquisition: insights from a microbicide trial. 

      Naranbhai, Vivek.; Altfeld, Marcus.; Abdool Karim, Quarraisha.; Ndung'u, Thumbi.; Abdool Karim, Salim Safurdeen.; Carr, William Henry. (Lippincott Williams & Wilkins., 2012-09-10)
      Objective: To assess the role of natural killer (NK) cells in HIV acquisition. Design: We conducted a nested case–control substudy to the Center for the AIDS Programme of Research in South Africa (CAPRISA004) tenofovir gel ...
    • Patients’ readiness to start highly active antiretroviral treatment for HIV. 

      Gebrekristos, Hirut T.; Mlisana, Koleka Patience.; Abdool Karim, Quarraisha. (BMJ publishing group., 2005-10-01)
      Assessing whether patients are ready to start antiretroviral treatment may improve HIV prevention and treatment outcomes.
    • A pilot study of once-daily antiretroviral therapy integrated with Tuberculosis directly observed therapy in a resource-limited setting. 

      Jack, Christopher.; Lalloo, Umesh Gangaram.; Abdool Karim, Quarraisha.; Abdool Karim, Salim Safurdeen.; El-Sadr, Wafaa.; Cassol, Sharon.; Friedland, Gerald H. (Lippincott Williams & Wilkins., 2004-08-01)
      To determine the feasibility and effectiveness of integrating highly active antiretroviral therapy (HAART) into existing tuberculosis directly observed therapy (TB/DOT) programs, we performed a pilot study in an urban ...
    • Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. 

      Abrahams, Melissa-Rose.; Anderson, Jeffrey A.; Giorgi, E. E.; Seoighe, Cathal.; Mlisana, Koleka Patience.; Liu, Pinghuang.; Athreya, G. S.; Treurnicht, Florette K.; Keele, Brandon F.; Wood, N.; Salazar-Gonzalez, Jesus F.; Bhattacharya, T.; Chu, Haitao.; Hoffman, Irving F.; Galvin, S.; Mapanje, Clement.; Kazembe, P.; Thebus, Ruwayida.; Fiscus, Susan.; Hide, Winston.; Cohen, Myron.; Abdool Karim, Salim Safurdeen.; Haynes, Barton F.; Shaw, George M.; Hahn, Beatrice H.; Korber, Bette T.; Swanstrom, Ronald.; Williamson, Carolyn. (American Society for Microbiology., 2009-04)
      Identifying the specific genetic characteristics of successfully transmitted variants may prove central to the development of effective vaccine and microbicide interventions. Although human immunodeficiency virus transmission ...
    • Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial. 

      Sokal, David C.; Abdool Karim, Quarraisha.; Sibeko, Sengeziwe.; Yende Zuma, Nonhlanhla.; Mansoor, Leila E.; Baxter, Cheryl.; Grobler, Anna Christina.; Frohlich, Janet A.; Kharsany, Ayesha B. M.; Miya, Nomsa.; Mlisana, Koleka Patience.; Maarschalk, Silvia.; Abdool Karim, Salim Safurdeen. (International Medical Press., 2013)
      Background: Tenofovir gel, used vaginally before and after coitus, reduced women’s acquisition of HIV by 39%. This is a safety assessment of tenofovir gel, including renal, bone, gastrointestinal, genital and haematological ...